Pharma News, 2022

The site in Kent will support the manufacture of regulatory approved cannabis-based medicines while also leveraging environmental practices.

A study published today in Nature Communications unveils a new platform for discovering cellular signatures of disease that integrates robotic systems for studying patient cells with artificial int...

The results show that all three ADAs studied (domperidone, metopimazine, and metoclopramide) were associated with an increased risk, especially in the first days of use, but the highest increase w...

Teva Pharmaceuticals has halted a phase 2 trial of TEV-48574, an investigational biologic drug for asthma patients, after interim results indicated that the treatment is unlikely to provide a signi...

An Aurobindo plant that received a scathing FDA rebuke several years back is shutting its doors for good.

Novartis has pushed its second radioligand therapy over the FDA finish line, and the Swiss pharma has more than $2 billion in peak sales expectation linked to the new launch. ...

Digital-first patient care is a priority as Huma and AstraZeneca join forces to improve patients' lives.

Roquette is investing €25 million at its site in Lestrem, France to strengthen its position in the polyols market.

Pfizer has recalled several lots of its blood pressure drug Accuretic (quinapril HCl/hydrochlorothiazide) as well as two generic versions of the drug because of possible nitrosamine contamination....

Fujifilm is expanding its footprint within the US yet again, this time with another East Coast acquisition within driving distance of its new $2 billion headquarters. ...

Eisai and Biogen have released more data on lecanemab, another anti-Alzheimer’s drug in the partnership that spawned aducanumab. 

BioAge Labs, Inc., a biotechnology company developing medications that target the molecular causes of aging to extend healthy human lifespan, today announced that its clinical-stage oral drug BGE-...